MedWatch

Two main factors behind Sanofi's dialog with Danish authorities

Of the six companies participating in the market consultation on vaccine production in Denmark, only Sanofi has an mRNA vaccine in development, which is what the Danish PM has called for. The French pharmaceutical giant does not agree to an interview, but relates that it has had a dialog with Danish authorities for two reasons.

Sanofi General Manager / Operational Head Vaccines Denmark, Norway & Iceland Per H. Aabakken | Photo: Sanofi/PR

French life science giant Sanofi is one of three global companies interested in producing vaccines in Denmark as part of a tender organized by the Danish government and the Danish State Serum Institute (SSI).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs